Wednesday, December 3, 2008

More clinical data to review

There was some news out for my portfolio companies today, including Isis Pharmaceuticals (calls 4.7% of portfolio), which announced that OncoGenex had released Phase 2 clinical data for OGX-011. The compound was jointly discovered and initially developed by the two companies; OncoGenex is developing it now with Isis as a partner. I have yet to analyze the results, I'll likely leave that for the weekend.